Gutzmer, R., Rivoltini, L., Levchenko, E., Testori, A., Utikal, J., Ascierto, P. A., . . . Lehmann, F. F. (2016). Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: Results of a phase I dose escalation study. BMJ Publishing Group.
Chicago Style CitationGutzmer, R., et al. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Metastatic Melanoma: Results of a Phase I Dose Escalation Study. BMJ Publishing Group, 2016.
MLA CitationGutzmer, R., et al. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Metastatic Melanoma: Results of a Phase I Dose Escalation Study. BMJ Publishing Group, 2016.
Warning: These citations may not always be 100% accurate.